Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Medium materiality6/10

SCNX Q3 Revenue up 256% on Arbli Growth and REZENOPY Launch

Oct 22, 2026, 8:12 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Stronger-than-expected top-line growth on a small base plus new product launches can lift sentiment and valuation, but the effect is tempered by the preliminary, unaudited nature and absence of margin data or guidance.

AI summary

What happened, with direct paths to the underlying reporting

SCNX reports preliminary unaudited Q3 revenue of about $1.22 million, up 256% sequentially, aided by Arbli growth and the commercial launch of REZENOPY. The data are early and subject to revision, but the momentum suggests meaningful progress in SCNX's product portfolio and near-term revenue potential, contingent on margins and subsequent updates.

Preliminary Q3 revenue rose 256% sequentially to $1.22M.
Growth driven by Arbli product and REZENOPY launch.
Figures are preliminary unaudited and subject to revision.
Commercialization progress could translate into sustained revenue momentum.
No additional data provided; near-term catalysts include launches and adoption.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.